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Abstract 
CTLA-4 is a critical ‘checkpoint’ regulator in autoimmunity. Variation in CTLA-4 isoform 
expression has been linked to type 1 diabetes development in human and NOD mouse studies. 
In the NOD mouse, a causative link between increased expression of the minor isoform, 
ligand-independent CTLA-4, and a reduction in diabetes has become widely accepted.  
Altered splicing of CTLA-4 has been attributed to a SNP in Ctla4 exon2 (e2_77A/G).  To 
investigate this link, we have employed NOD embryonic stem (ES) cells to generate a novel 
NOD transgenic line with the 77A/G single nucleotide polymorphism (SNP).  This strain 
phenocopies the increase in splicing towards the liCTLA4 isoform seen in B10 Idd5.1 mice.  
Crucially, the SNP does not alter the spontaneous incidence of diabetes, the incidence of 
cyclophosphamide-induced diabetes or the activation of diabetogenic TCR transgenic CD4+ 
T cells after adoptive transfer.  Our results show that one or more of the many other linked 
genetic variants between the B10 and NOD genome are required for the diabetes protection 
conferred by Idd5.1. With the NOD mouse model closely mimicking the human disease, our 
data demonstrate that knock-in transgenic mice on the NOD background can test causative 
mutations relevant in human diabetes. 
The development of most autoimmune diseases, including type 1 diabetes, is influenced by 
both genetic and environmental factors.  Such genetic susceptibility is complex.  In addition 
to polymorphisms in MHC genes, there are many genetic variants which contribute to 
diabetes susceptibility, each of which contributes a relatively small additional risk.  In man, 
genome wide association studies have identified more than 40 genetic traits which affect type 
1 diabetes susceptibility; a similar number of genetic intervals have been identified in the 
NOD mouse model (1). Variation which alters the mRNA splicing of CTLA-4 has been 
implicated in diabetes susceptibility in both man and the NOD mouse model (2).  CTLA-4 
polymorphisms are also associated with type 1 diabetes susceptibility in dogs (3). 
CTLA-4 is an important immunoregulatory molecule with an essential role in the function of 
regulatory T cells  (4; 5)and a less well-defined role in effector T cells (6; 7). In humans two 
protein isoforms have been described, the canonical transmembrane homodimer (flCTLA4) 
and a soluble monomeric form (sCTLA4); both forms result from alternative mRNA splicing 
of the nascent CTLA-4 transcript and both bind to the Immunoglobulin superfamily ligands 
CD80 and CD86.  In addition to these two forms, a third protein isoform, liCTLA-4 has been 
described in mice. This isoform results from alternative mRNA splicing in which exon 2 
(encoding the ligand binding Ig domain) is spliced out to produce a predicted 72aa mature 
transmembrane protein capable of homo- or hetero-dimerization with li/flCTLA4 (8).  Ueda 
et al. (2) found an association between lower expression levels of the soluble isoform of 
CTLA4 and susceptibility to autoimmune diseases, including type 1 diabetes, in humans and 
also showed that NOD mice but not NOD.B10Sn-Idd5 mice had lower levels of mRNA for 
the liCTLA4 isoform.  Subsequent work by Wicker and colleagues has confirmed the close 
correlation between genetic variation in Ctla4, variation in liCTLA4 mRNA expression and 
diabetes susceptibility in a number of NOD congenic mouse strains (9; 10).  Indeed, the 
protection from diabetes observed in NOD.B10Sn-Idd5.1 mice is now widely attributed to 
Ctla4, in particular to the A/G SNP at position 77 in Ctla4 exon 2 (11-13). 
While the correlation between diabetes protection and increased levels of liCTLA is 
suggestive, it does not demonstrate a causal link.  Furthermore, there has been no direct test 
of the hypothesis that the exon 2 SNP is responsible for the alteration in mRNA splicing.  We 
recently developed germline competent ES cells from the NOD strain (14). We therefore 
decided to directly test whether this SNP is responsible for altering splicing efficiency and 
diabetes susceptibility.  We have derived a novel ‘knock-in’ transgenic strain on the NOD 
background which contains the candidate causative B10 SNP (Ctla4 e2_77A).  Analysis of 
this mouse strain demonstrates that the SNP is fully responsible for the change in alternative 
mRNA splicing and that the increased expression of liCTLA4 does not alter the susceptibility 
to diabetes.   
 Research Design and Methods 
 
Mice 
NOD/MrkTacDil, NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/DoiJ, NOD.Cg-N(Foxp3-I-
EGFP) and NOD 77A (official name NOD-Ctla4tm1(77A)Holm) mice as well as their crosses 
were bred under specific pathogen free conditions at the Biological Services Unit of the 
Department of Pathology, Cambridge, UK. Mice had unrestricted access to standard 
laboratory food and water and were housed in open or air filtered cages. All animal work was 
carried out in accordance with UK Home Office project and personal licences and was 
approved by the Ethical Review Committee of the University of Cambridge. 
 
 
ES cell culture and blastocyst injection. 
 
Clone 16 NOD ES cells and their derivatives were maintained in N2B27medium 
supplemented with  1  of the MAPK inhibitor PD0325901 and 3  of the glycogen 
synthase kinase-3 inhibitor CHIR99021 (2i; both synthesized in the Division of Signal 
Transduction Therapy, University of Dundee, Dundee, UK) plus LIF (25 ng/mL, produced in 
house).  We injected 10–15 trypsinized NOD ES cells into each C57BL/6 blastocyst and then 
transferred the blastocysts to the uterus of a pseudopregnant F1 female mouse at 2.5 days post 
coitum. We assessed the resulting chimeras for germline transmission by mating them with 
NOD mice. 
 
 
Gene targeting 
The NOD BAC CH29-120A16 was obtained from the Children’s Hospital Research Center 
Oakland, Oakland CA.  A 10,047bp SpeI-SacI fragment which contained CTLA-4 was cut 
from the BAC sequence and inserted into a SacI-XbaI cut pNEB193 vector. This 10,047bp 
fragment was in turn cut with SacI-KpnI and KpnI-PacI, producing two fragments which 
contained the 5' and 3' arms of the CTLA-4 gene respectively, which were subcloned into 
pNEB193.  The 3' arm was modified by insertion of a selection cassette into the NsiI site in 
intron 2. The selection cassette consisted of  a loxP flanked Neomycin resistance gene and a 
Herpes Simplex Virus Thymidine Kinase gene, both driven by an enhancerless thymidine 
kinase promoter from plasmid, pNeoTKloxP (Peter McKinnon, St. Jude Children's Research 
Hospital, Memphis).  The 5'‘ ARM was modified by substitution of a 236bp DraIII-KpnI 
fragment containing a single GA point mutation  at position 77 of exon 2.  The two arms 
were rejoined at the KpnI site the resulting plasmid linearised with NotI and 107 clone 16 
male NOD ES cells (14) cells transfected by electroporation. Transfected cells were subjected 
to G418 selection in 2i media and any surviving cells were cultured as individual clones in 96 
well plates. 
Homologous recombinants were identified by PCR screening with a 3 primer assay which 
amplified distinct products from targeted and endogenous loci (primers P1+P3+P4; see  Table 
1).   Recombinants were confirmed by Southern blotting with both a 5' flanking and internal 
probe and the co-integration of the targeted 77A mutation confirmed by sequencing. The loxP 
flanked cassette was removed by transient transfection with a CAGGS-Cre-Ires-Blasticidin 
plasmid (Sandra Gomez-Lopez, Cambridge Stem Cell Institute). 24 hours after transfection 
cells were exposed to Blastocidin for 24hrs and candidate clones were picked from surviving 
cells.  The structure of the recombined locus was confirmed by sequencing. 
 
Monitoring of glucose levels 
Urine glucose levels were measured using indicator strips) and readings of >28mM glucose 
in the urine were considered diabetic (rated according to the colour-glucose-scale provided by 
the manufacturer). Glucose readings were taken between 15:00 and 18:00 hours in the 
afternoon, except where stated otherwise. Only female mice were used for spontaneous 
diabetes incidence studies. 
 
Cyclophosphamide (CTX) injections 
All mice were weighed and tested for hyperglycaemia prior to injections. Only healthy male 
mice were injected intraperitoneally with 20 mg/ml CTX solution at a dose of 250mg/kg. 
Mice were held in a supine position and injections were made in the lower left quadrant of 
the abdomen. Following injection, mice were tested for hyperglycaemia every 24 hours for 4 
weeks. 
 
 
Quantitative PCR 
For template generation, cells were lysed using the QIAshredder kit and RNA was extracted 
using the Rneasy kit DNA contaminants were removed using the TURBO DNA free kit and 
the mRNA was reverse transcribed using the SuperScript III First Strand Synthesis System 
RNA sequence bias was avoided by using Oligo (dT)20 primers for cDNA synthesis. RNA 
content in all reactions was optimised to maximise cDNA concentration. 
 
Quantitative PCR assays were performed in triplicate or quadruplicate with water controls 
included on every plate and housekeeping gene controls included for every sample. Reactions 
contained 10l of the relevant primer mix (2x), 10l of GoTaq qPCR Master Mix  and 
approximately 1ng of cDNA template. Primer sequences are shown in  Table 2. 
 
Samples were analysed using the Applied Biosystems 7500 Fast Real-Time PCR System 
calibrated for SYBR green detection. All plates were run using the same amplification 
program: 95°C for 15min, (94°C for 15s, 60°C for 30s, 72°C for 30s) x 40 cycles followed by 
a dissociation stage. The threshold for detection was set within the linear phase of the 
logarithmic amplification plot. 
  
CFSE labelling 
For CFSE labelling, CD4+ splenocytes were incubated with 1M CFSE in PBS at a 
concentration of 107 cells/ml. Cells were incubated for 15 minutes at 37°C and washed twice 
with cold IMDM. Labelled cell pellets were re-suspended in IMDM at a concentration of 
5x106 cells/ml and injected into the tail veins of recipient mice (106 cells per mouse). 
 
Flow cytometry and cell sorting 
Cells were labelled with anti-CD4 (RM4-5) supplemented with 2.4G2 anti-FcγRII/III 
(produced in house). Labelled cells were analysed using the Cytek DxP8 flow cytometer. 
 
Cells for use in qPCR were isolated using the MoFlo cell sorter and cells for CFSE labelling 
were isolated using magnetic-activated cell sorting of anti-CD4(L3T4) conjugated magnetic 
beads  
 
Cell culture 
For T cell activation, culture dishes were coated with 10g/ml anti-CD3 antibody (145-2C11 
produced in house) overnight. Purified T cells were cultured in IMDM medium supplemented 
with 10% FCS, 100 U/ml Penicillin, 100 g/ml Streptomycin, 2mM glutamine and 5g/ml 
anti-CD28 antibody (37.51 also produced in house). 
 
 
Results  
Generation of a NOD transgenic bearing the Ctla4 exon 2 SNP 77A  
 
NOD strain ES cells were maintained in ground state by culture in 2i medium (14) and 
transfected with a Ctla4 targeting construct. The construct was prepared using the NOD 
bacterial arteficial chromosome (BAC) CH29-120A16 as an isogenic DNA source and 
contains a single GA point mutation at position 77 in exon 2 (see Research Design and 
Methods). The final genomic structure (R2, Fig. 1A) retains a single loxP site within intron 2.  
23 male chimeras were produced by injecting clone 3E1/11 ES cells into C57BL/6 
blastocysts.  11 chimeras, chosen for strong NOD coat color contribution, were backcrossed 
to our NOD colony; 54% of offspring were ES cell derived and 31.25 % of these carried the 
targeted Ctla477A allele (difference in allelic transmission not significant).  The breeding 
scheme for producing incidence cohorts for analysis is shown in Fig.1B. Heterozygous 
77A/G NOD offspring were intercrossed to produce both 77A/A and 77G/G homozygotes; 
from here on referred to as NOD 77A and NOD 77G. These first generation homozygotes 
were again intercrossed to produce sufficient female offspring for study (Incidence cohort I).  
In this way, the experimental and control cohorts shared all ES derived genetic material 
except Ctla4 and its linked genomic segment.  A second cohort set was produced after a 
further backcross to our NOD colony, with the gender of the NOD parent reversed (Fig. 1B).  
First generation 77A homozygotes were also crossed to our NOD.Cg-BDC2.5 and NOD.Cg-
FoxP3EGFP colonies. Sib-mating of the offspring produced 77A homozygotes carrying the 
relevant transgene. FoxP3EGFP was also made homozygous whereas the BDC2.5 TCR 
transgenes were maintained by screening. 
 
 
 
The 77A mutation in Ctla-4 exon 2 controls mRNA splicing and increases liCTLA-4 
expression 
 
We examined the effect of the 77A mutation on CTLA-4 mRNA splicing by measuring the 
mRNA levels of each CTLA-4 isoform in the T cells of NOD 77A Foxp3EGFP and NOD 77G 
Foxp3EGFP mice. Three different T cell populations, conventional T cells (CD4+Foxp3-), 
regulatory T cells (CD4+Foxp3+) and in vitro activated T cells (CD4+FoxP3- stimulated with 
anti-CD3 + anti-CD28) were investigated. CTLA-4 mRNA was most abundant in regulatory 
T cells which in comparison to in vitro activated T cells and conventional T cells contained 
six fold and sixty seven fold more CTLA-4 mRNA, respectively (Fig. 2A). Analysis of the 
different CTLA-4 isoforms revealed that the ligand independent and soluble isoforms are rare 
compared to the full length isoform which represents between 86 and 99% of the total CTLA-
4 mRNA (Fig. 2 B,C,D). 
 
In all analysed T cell populations, the introduction of the 77A mutation resulted in a 
significant increase of liCTLA-4 mRNA. A two-fold increase in liCTLA-4 was observed in 
conventional and regulatory T cells and a fourfold increase was observed in in vitro activated 
cells (Fig. 2C). Considering that all isoforms are spliced from the same pre-mRNA, any 
increases in exon 2 splicing were expected to decrease the abundance of full length and 
soluble isoforms (Fig. 2 B,D). These results directly demonstrate, for the first time, that the 
77A mutation in CTLA-4 exon 2 enhances the effectiveness of the exonic splicing silencer 
motif. Given the importance of CTLA-4 in immune regulation, the immunological relevance 
of this change in mRNA expression was explored. 
 
The 77A mutation and associated increases in liCTLA-4 expression do not affect 
spontaneous or induced diabetes development in the NOD mouse 
Spontaneous diabetes incidence in female mice represents the most powerful immunological 
readout of the NOD model and we therefore investigated spontaneous incidence in our gene 
targeted NOD colonies. The first cohort study was conducted on animals which contained 
equal amounts of NOD ES cell derived and 'colony NOD' derived genetic material (Fig. 1B). 
The main onset of diabetes in this cohort occurred around 15 weeks of age and the total 
incidence levelled off between 60 and 70%. The 77A mutation had no significant effect on 
spontaneous diabetes development (Fig. 3A). Mice backcrossed a second time, now  
containing only 25% ES cell derived genetic material, were investigated in a second 
incidence study (Fig. 3B). With diabetes onset at 12 weeks of age and a total incidence above 
80% the backcrossed NOD 77A and 77G mice mirrored the diabetes incidence of the 
originator colony. Despite the increased cohort size, no difference between the NOD 77A and 
NOD 77G cohorts could be distinguished (Fig. 3B). The 77A mutation and altered levels of 
liCTLA-4 do not therefore affect spontaneous diabetes development. The difference in 
incidence between the initial and backcrossed cohorts may be due to variation in the 
environment as all mice were moved from open cages into individually ventilated cages 20 
weeks into the first study. Also, the possibility that both initial cohorts were affected by 
genetic or epigenetic changes occurring during ES cell culture, and lost after the second 
backcross, cannot be ruled out. 
 
To explore the possibility of only certain functions of the immune system being linked to the 
77A mutation, we compared the cyclophosphamide (CTX) induced diabetes incidence in 
male NOD 77A and NOD 77G mice. CTX is thought to induce diabetes by depleting mature 
lymphocytes in the periphery which leads to the preferential repopulation of lymphoid niches 
by diabetogenic effector T cells and hence the preclusion of regulatory T cells (15; 16). 12 
week old mice received a single intraperitoneal injection of 250 mg/kg CTX and urinary 
glucose was monitored for 3 weeks. In both strains the fastest rate of diabetes development 
was reached on day 10 post injection and a total of 70-80% of mice developed diabetes by 
day 21 (Fig. 3C). No effect of the 77A mutation was observed, suggesting that the capacity of 
diabetogenic T cells to repopulate lymphoid niches was not affected by the 77A mutation or 
physiological changes in liCTLA-4 (Fig. 3C). These data appear at odds with the published 
result of Stumpf et al. (17) who did see a reduction in CTX-induced diabetes in NOD 
background mice with similarly increased liCTLA4.  There are a number of experimental 
differences however.  One of these was that younger mice were given two injections of 200 
mg/kg CTX seven days apart (17). We therefore used this protocol to determine whether the 
77A mutation conferred any protection from diabetes onset. We could find no evidence for 
this (data not shown); indeed the majority of mice given one injection of 200mg/kg CTX at 8-
10 weeks developed diabetes by 7 days later (see Discussion for further consideration of 
these differences).  
 
Physiological increases in liCTLA-4 mRNA have no measurable effect on T cell 
activation, proliferation or regulatory function 
To directly assess the effect of liCTLA-4 mRNA variation on immune function, we used 
BDC2.5 transgenic NOD 77A and NOD 77G control mice. T cells in these mice express the 
T cell receptor (TCR) from BDC2.5, a diabetogenic T cell clone (18).  When transferred to 
adult NOD mice, BDC2.5 transgenic T cells undergo antigen-driven proliferation in the 
pancreatic lymph node (19). CD4+ T cells were isolated from BDC2.5 transgenic NOD 77A 
and NOD 77G mice, in vitro labelled with the proliferation dye CFSE and adoptively 
transferred into wild type NOD recipients. After 72 hours cells were recovered from the 
pancreatic lymph nodes of recipient mice and analysed by flow cytometry (Fig. 4). In all 
recipient mice, a proportion of transferred T cells were dividing, visualised by the typical 
pattern of division peaks (Fig. 4B,C,D,E). To directly compare the proliferative properties of 
77A and 77G derived BDC2.5 T cells, proliferation profiles were averaged and overlaid (Fig. 
4F). No significant effect of increased liCTLA-4 levels on T cell proliferation could be 
observed. Alternative analysis of this data, comparing the number of cells that remained 
undivided also showed no significant impact of liCTLA-4 mRNA (data not shown). These 
data strongly suggest that the TCR activation threshold which represents the cell’s 
immunological state, as well as the dynamics of cell proliferation, is not affected by the 77A 
induced changes to liCTLA-4 mRNA. 
 
We also assessed the function of regulatory T cells using an in vivo adoptive transfer model.   
T cells from BDC2.5 mice induce rapid diabetes when transferred to NOD-SCID recipients; 
the co-transfer of CD25hi Tregs
 
can prevent or delay diabetes onset in the NOD-SCID mice 
(20).   BDC2.5 transgenic NOD 77A mice were crossed with the NOD.Cg-FoxP3EGFP strain.  
This enabled the preparation of Treg-depleted effector populations (CD4+GFP-) and Tregs 
(CD4+CD25hiGFP+) from the same donors.  Co-transfer of Tregs with effector T cells in a 
ratio of 1:3 delayed but did not prevent diabetes onset (Fig. 5). However, there was no 
discernible difference between the effectiveness of the Tregs from 77A and 77G genotypyes 
(Fig. 5).  This experimental model reinforces the conclusion that there is no difference in the 
ability of 77A effectors to cause diabetes and shows that effectors from 77A and 77G 
genotype NOD mice are equally responsive to regulation by cognate Tregs of the same 
CTLA4 genotype (Fig. 5). 
 
Discussion 
 
A number of previous studies have provided evidence for the hypothesis that increased levels 
of mRNA splicing to the liCTLA4 isoform have functional consequences in T cells and, in 
congenic NOD strains, reduce the incidence of spontaneous and/or induced diabetes (8-10; 
17).  We believe that our data (Fig. 3) clearly contradicts the conclusion that a modest (2-4-
fold) increase in liCTLA4 levels produced by the GA single nucleotide substitution at exon 
2 position 77 alters the spontaneous or induced diabetes susceptibility in NOD mice. For the 
most part, significant experimental differences easily account for the differing conclusions of 
our study with those previously published.  In the work of Wicker and her colleagues, NOD 
congenic strains were painstakingly derived with introgressed genomic DNA from the Idd5.1 
region from the CAST and SWR strains in addition to the original B10Sn-Idd5.1 strain (10). 
NOD.CAST-Idd5.1 had a greater increase in liCTLA4 mRNA than the B10 congenic while 
NOD.SWR-Idd5.1 mirrored the NOD level; the presence of a single copy of CAST-Idd5.1 
was sufficient to reduce the spontaneous incidence of diabetes by nearly half but two copies 
of SWR-Idd5.1 made no difference to diabetes susceptibility.  However, in all the NOD 
congenics which shared the Ctla4 77A variant, it was accompanied by a very large number of 
other linked genetic variants differing from the NOD genome, so that the correlation was 
suggestive but by no means conclusive.  In our mice, the only known genetic differences 
between our two cohorts are the 77A variant and the presence of a loxP site in Ctla4 intron 2. 
 
Araki et al. (10) also found that NOD mice transgenic for a CD2-driven liCTLA4 cDNA 
developed diabetes at a reduced frequency.  Here, the link of function to expression of 
liCTLA4 mRNA and protein is direct and the mice are 100% NOD genetically except for the 
transgene.  However, the transgenic construct produced an approximate 2000-fold increase in 
the liCTLA4 mRNA level and it is plausible that such an overexpression might have 
adventitious consequences, for example by sequestering miRNAs. A more physiological 
increase in the level of liCTLA4 mRNA was produced by transgenesis with a C57BL/6 BAC 
clone encoding Ctla4. The BAC was modified so that exon 2 was flanked by loxP sites.  
Intercrossing with a Vav1-Cre deleter strain should produce mice whose hemopoetic cells 
contain a Cre-recombined transgene, capable of only producing liCTLA4 (17).  These mice, 
termed NOD-Tg-Cre, were shown to have a 2-fold increase in liCTLA4 mRNA in 
CD4+CD25hiCD62L- cells.  Surprisingly, Stumpf and colleagues (17) do not describe the 
effects of the transgene on the spontaneous incidence of diabetes.  The most directly 
comparable experiments reported are reduced incidence of pancreatic infiltration (scored by 
histology) in 20 week-old pre-diabetic mice and a reduced incidence of diabetes in 8 week-
old mice treated with a 2 dose CTX regime.  Neither experiment reports the gender of the 
mice used so we cannot be sure we are making correct comparisons, however we saw no 
significant difference in immune cell infiltration in 12 week-old females (data not shown) and 
no difference in diabetes incidence in CTX-treated males (Fig. 3C).  The BAC transgenic was 
produced by microinjection into NOD embryos, however the Vav1-Cre transgene was made 
in (CBA/Ca×C57F7BL/10)F1 mice (21).  Some non-NOD genomic DNA is present in the 
NOD-Tg-Cre mice even though the Vav1-Cre strain had been backcrossed to NOD.  It also 
seems likely that the USCF colony has a lower incidence of diabetes; their NOD mice took 
16 days to develop diabetes after 2 injections of CTX whereas we find diabetes starts at about 
1 week after a single injection when given at 8-10 weeks of age.  In addition, we have to 
conduct our insulitis screen at 12 weeks since 40-50% of our colony is diabetic by 20 weeks 
of age (Fig. 3B). These probable differences in diabetes incidence could be the result of 
genetic or environmental factors or a combination of both. 
 
The data reported here are the most direct (and simple) test of the functional effects of the 
modest increase in liCTLA4 mRNA produced by the exon 2 77A SNP and we contend that 
the incidence data are conclusive in showing that this mRNA splicing change does not alter 
diabetes susceptibility.  The clear implication is that one or more of the >700 other genetic 
differences between the NOD and C57BL10/Sn-Idd5.1 strains (9), possibly affecting other 
genes e.g. Icos, are required for the change in diabetes incidence previously reported (9; 10).  
We do not exclude that the exon 2 77A SNP may be necessary for the diabetes phenotype but 
neither it nor the splicing change are sufficient. This study demonstrates that NOD ES cells 
can provide a probative test of candidate mutations in diabetes susceptibility.  Further studies 
using NOD ES cells carrying multiple or single genetic differences could resolve the 
ambiguities which surround causative mutations in genetic susceptibility to diabetes and 
provide models for probing mechanisms of protection,  in many cases directly relevant to 
human disease (22). 
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 Table 1:    List of genomic screening primers. 
 
Primer ID  and target Sequence 
P1   3 prime flanking primer GGGCAGCCCATAAAACAATC 
P3   non-recombinant forward TTCTCCTTGCCATAGCCAAC 
P4   targeted locus specific forward CCACGACCCAAGCTGTATAA 
 
  
Table 2:   List of qPCR primers. 
 
Target  FWD ID and Sequence REV ID and Sequence 
flCTLA4 PQ1   CGCAGATTTATGTCATTGATCC PQ2   TTTTCACATAGACCCCTGTTGT 
liCTLA4 PQ3   CCCAGTCTTCTCTGAAGATCC PQ2   TTTTCACATAGACCCCTGTTGT 
sCTLA4 PQ4   CGCAGATTTATGTCATTGCTAA PQ5   TCATAAACGGCCTTTCAGTT   
pgk1 PHK5  CAGCTAGTGGCTGAGATGTG PHK6  ATAGACGCCCTCTACAATGC 
beta2m PHK7  GGAAGCCGAACATACTGAAC PHK8  AGAAAGACCAGT CCTTGCTG 
   
   
 
 
Figure Legends  
 
Figure 1. 
Generation of the NOD-Ctla4tm1(77A)Holm strain and pedigree. 
A. The targeting construct and recombination strategy in NOD ES cells. R1 shows 
the structure of the Ctla4 locus after the first recombination and R2 after Cre deletion.  
The actual sequence difference from NOD germline is shown in red below.  B. The 
pedigree of NOD 77A and NOD 77G control strains beginning with NOD ES 
cell.C57BL/6 chimeras; numbers of animals at each step are shown, where a subset 
were used for breeding, the number bred is in brackets. 
 
 
Figure 2. 
 
The 77A mutation increases liCTLA-4 isoform expression in T cells. 
CD4+Foxp3- and CD4+Foxp3+ splenocytes were isolated from 7-9 wk old female 
NOD 77A Foxp3EGFP (triangles, n=10) and NOD 77G Foxp3EGFP (circles, n=13) mice. 
For in vitro activation, CD4+Foxp3- cells were cultured with anti-CD3/anti-CD28 for 
48 hours. qPCR analysis reveals total CTLA-4 expression (A) as well as the 
contribution flCTLA-4 (B), liCTLA-4 (C) sCTLA-4 (D) to the total CTLA-4 mRNA pool 
in both mouse strains. Statistical analysis was performed using the non-parametric 
Mann-Whitney test. Median values are indicated as black bars. The data are pooled 
from 3 independent experiments 
 
 
Figure 3. 
 
Spontaneous and induced diabetes incidence is not affected by increased 
expression of liCTLA-4. Spontaneous diabetes incidence in female mice of the 
initial cohort (A) and the backcrossed cohort (B) was determined through weekly 
urine glucose measurements. No significant difference in spontaneous incidence 
was found in either cohort (Log-rank, A: p=0.4697, B: p=0.329).  C. In 12 wk old 
male mice, diabetes was induced by a single injection of 250mg/kg CTX. Urine 
glucose measurements were taken daily for three weeks. No significant difference in 
induced incidence was found (Log-rank, p=0.8646). In all incidence studies mice with 
two consecutive readings of >28mM glucose in the urine were considered diabetic. 
Numbers of animals are shown in figures.  A and B show both replicates, data in C 
are pooled from 2 experiments. 
 
 
 
 
Figure 4. 
 
Antigen specific T cell activation and proliferation are not affected by 
increased expression of liCTLA-4. A. CD4+ splenocytes were isolated from 8-9 wk 
old male 77A (triangles, n=14) or 77G (circles, n=13) control BDC2.5 NOD mice; the 
data are pooled from 3 experiments. Sorted cells of either genotype were CFSE 
labelled and injected i.v. into 6-8 week old male wt NOD mice. 72 hours post transfer, 
cells were recovered from the pancreatic LNs of recipient mice.  Recovered cells 
were stained with anti-CD4-APC  and analysed.  Panels B and C show results from 
an example mouse.  B. Cells are gated for FSC/SSC.  C.  CD4+CFSE+ cells gated 
from panel B were analysed for CFSE intensity  D. E.  Individual division profiles for 
each mouse are summarised for NOD 77A T cells (D) and NOD 77G T cells (E). The 
dividing cells within each peak are displayed relative to the total number of dividing 
cells. F.  Average division profiles of NOD 77A (closed triangles,solid line and NOD 
77G (open circles, dotted line) transfers closely correlate (Pearson r=0.988, 
p=0.0016). 
 
Figure 5  
Increased expression of liCTLA4 does not impair regulatory T cell activity in an 
adoptive diabetes transfer model.  T cells were isolated from 12 week old female 
77A or 77G Foxp3EGFP-BDC2.5 NOD mice. 2x105 CD4+GFP- Teffector cells were  
injected (i.v.) alone (open symbols, dotted lines: 77A genotype= squares, 
77G=circles) or together with 0.7x105 CD4+CD25hiGFP+ Treg cells from the same 
mice (closed symbols, solid lines: 77A genotype= squares, 77G=circles) into 8 week 
old NOD SCID mice. Following the adoptive transfer, blood glucose levels were 
tested daily between 11:00 and 13:00 hours for 2 weeks. Mice with two consecutive 
readings of >13.9mM glucose in the blood were considered diabetic.  Tregs from 
both 77A and 77G genotypes delayed the onset of diabetes significantly (TeffA vs 
Treg+effA; p=0.0005. TeffG vs Treg+effG; p=0.0024 ; Log-Rank test) but there was 
no significant difference between the potency of the effectors or Tregs from the 
different CTLA4 genotypes
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